TScan Therapeutics Inc. (NASDAQ:TCRX), a biotechnology company focused on developing T cell receptor-engineered T cell (TCR-T) therapies, has been making waves in the oncology treatment landscape.

TScan Therapeutics (TScan) is a clinical-stage biotechnology company. It focuses on the development of T cell receptor (TCR) engineered T cell therapies to treat cancer. The company’s pipeline ...

Shares of TCRX opened at $3.02 on Wednesday. TScan Therapeutics has a 1 year low of $2.60 and a 1 year high of $9.69. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.56 and a ...

Ratings for TScan Therapeutics TCRX were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below offers a condensed view of their ...

TScan Therapeutics (TCRX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on the ...

To date, event-free survival strongly favors the treatment arm (HR=0.30; p=0.04), and treatment-arm patients trend towards lower probability of relapse (HR=0.28; p=0.14) No dose-limiting ...

Investing.com - Tscan Therapeutics (NASDAQ: TCRX) reported first quarter EPS of $-0.21, $0.08 better than the analyst estimate of $-0.29. Revenue for the quarter came in at ...

TScan Therapeutics, Inc. WALTHAM, Mass., Dec. 05, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell ...

WALTHAM, Mass., Dec. 05, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell ...

“This is the third consecutive year that TScan has been recognized as a Top Place to Work, an achievement that reflects the dedication, inclusivity, and employee-centric values that define our ...